As the efficacy of GLP-1 receptor agonists and ketogenic diets in treating obesity and metabolic diseases gains momentum, the healthcare sector is also grappling with diverging definitions of Alzheimer’s disease. In response, stakeholders are forming a working group to standardize diagnostic criteria, aiming to mitigate risks in patient care and policy consistency. Despite concerns over Alzheimer’s classification, the clinical landscape remains stable with strong support for metabolic interventions and no significant immediate threats to ongoing research.
Title not available for this citation.
“The ketogenic VLED resulted in significantly greater reduction in hepatic steatosis and weight loss compared to a MD.”
Title not available for this citation.
“The VLED also produced greater TBWL at week 12 (-13% [IQR -17 to -9] vs. -4% [-4.4 to -0.2], p <0.01).”
Title not available for this citation.
“The accessibility, effectiveness, and feasibility of the VLED in clinical settings suggest that it may represent a valuable therapeutic option for selected patients with MASLD and overweight or obesity.”
Title not available for this citation.
“Obesity is a multifactorial metabolic condition characterized by dysregulated lipid accumulation and systemic energy imbalance with escalating global prevalence.”
Title not available for this citation.
“This chronic disease drives a spectrum of life-threatening comorbidities, including metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH), which now represent a primary cause of liver-related morbidity and transplantation.”
Title not available for this citation.
“Although US Food and Drug Administration-approved antiobesity agents such as glucagon-like peptide-1 receptor agonists (eg, semaglutide) demonstrate weight loss efficacy, their long-term utility is constrained by gastrointestinal intolerance and variable effects on hepatic outcomes.”
Title not available for this citation.
“Natural products, with inherent structural diversity and multitarget potential, offer a promising avenue for dual intervention in the obesity-MASH continuum.”
Title not available for this citation.
“Prescription of a GLP-1 RA was associated with a lower risk of subsequent MACCE than phentermine-topiramate.”
Title not available for this citation.
“In the pre-weighting cohort, GLP-1 RA use was associated with decreased hazard of MACCE compared to bupropion-naltrexone.”
Title not available for this citation.
“GLP-1 agonists were more effective than control in reducing body weight, HbA1c, BMI z, and blood pressure.”
Title not available for this citation.
“Moreover, GLP-1 agonists were well tolerated, and the total adverse events and hypoglycemia were comparable to those of controls.”
Title not available for this citation.
“Semaglutide shows potential in cardiovascular protection, yet its specific role and mechanism in H/R injury are unclear.”
